At ASMS 2026, the Technology Networks team spoke with Dr. Konstantinos Thalassinos, Professor of Mass Spectrometry at University College London, about how advanced mass spectrometry is transforming the study of protein misfolding diseases. These disorders, including Alzheimer's disease, Huntington's disease, and type 2 diabetes, are driven by proteins adopting abnormal structures and forming harmful aggregates.
In this interview, Konstantinos discusses how improvements in mass spectrometry sensitivity are enabling researchers to capture elusive protein intermediates, uncover disease mechanisms, and advance the development of future therapeutics.
